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ABSTRACT
A nationwide voluntary laboratory-based surveillance study of invasive Streptococcus pyogenes (group A
streptococcus; GAS) infections was conducted in Germany between 1996 and 2002. Demographical and
clinical information concerning the patients was obtained from the medical ﬁles. Multiple logistic
regression analysis was used to determine risk-factors for fatal outcome. Invasive isolates were obtained
from 475 patients, with 251 (52.8%) of the isolates cultured from blood. The most frequent emm types
were emm1 (36.4%), emm28 (8.8%) and emm3 (8%). The speA, speC and ssa genes were present at variable
frequencies in different emm types. The highest frequencies of speA and speC were found in emm1 (speA,
93.6%) and emm4 (speC, 94.7%), respectively. The estimated annual incidence of invasive GAS disease
for 1997–2002 was 0.1 cases ⁄ 100 000 individuals. This apparently low incidence rate might be explained
by the voluntary nature of the surveillance system, resulting in relatively few cases being referred to the
laboratory. Complete clinical information was available for 165 cases. The overall case fatality rate was
40.6%, and was highest (65.2%) in the group aged 60–69 years. Shock, an age of ‡30 years and adult
respiratory distress syndrome were predictors of a fatal outcome in a multiple logistic regression
analysis. Overall, 6.7% of the cases were considered to be nosocomial, and nine cases of puerperal sepsis
were observed. The study underscores the importance of invasive S. pyogenes disease in Germany.
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INTRODUCTION
Streptococcus pyogenes (Lanceﬁeld group A strep-
tococcus; GAS) is a major human pathogen that
causes both suppurative and non-suppurative
infections, including pharyngitis, necrotising
fasciitis (NF) and streptococcal toxic shock
syndrome (STSS). NF and STSS are associated
with high morbidity and mortality rates [1,2].
Invasive infections caused by S. pyogenes have
been reported increasingly since the late 1980s [3].
Suppurative infections and post-infection seque-
lae, e.g., acute rheumatic fever, rheumatic heart
disease and glomerulonephritis, result in sub-
stantial human morbidity. The burden of invasive
S. pyogenes disease is high, with at least 663 000
new cases and 163 000 deaths worldwide each
year. In addition, there are >111 million current
cases of S. pyogenes pyoderma and >616 million
cases of pharyngitis annually [1].
The emm gene, which encodes a major virulence
factor, the M protein, is used as the basis
for typing S. pyogenes. The extensive N-terminal
variability of the M protein forms the basis for
the distinction of >170 emm types designated in
the S. pyogenes emm sequence database (http://
www.cdc.gov/ncidod/biotech/strep/emmtypes.
htm). Marked changes in the distribution of emm
types circulating in Europe were noted from the
late 1980s onwards [3,4], with emm1 and, to a
lesser extent, emm3 being associated frequently
with outbreaks and fatal outcome.
In Germany, data concerning the emm gene
distribution and epidemiological characteristics of
isolates of S. pyogenes from invasive disease have
not been available previously [5]. For non-invasive
disease, limited data are available concerning 216
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consecutive isolates of S. pyogenes from patients
with pharyngitis in the region of Aachen, Ger-
many, indicating that emm1 was the most common
emm type (18.5%), followed by emm12 (15.7%),
emm3 (14.4%) and emm28 (13.9%) [6]. The aim of
the present study was to identify the predominant
emm types among a large collection of S. pyogenes
isolates from invasive infections, and to deﬁne the
incidence and demographical risk-factors for
acquisition of invasive S. pyogenes infection in
Germany.
MATERIALS AND METHODS
Study design
A nationwide voluntary laboratory-based surveillance study
of invasive S. pyogenes infections was conducted in Germany
between 1996 and 2002. Isolates were sent to the National
Reference Center for Streptococci (NRCS; Aachen, Germany),
where the isolates were checked against the criteria for
inclusion in the study. An invasive infection was deﬁned
(according to the 1993 deﬁnition of the Working Group on
Severe Streptococcal Infections [7]) as the isolation of S. pyog-
enes from either a normally sterile sample (e.g., blood,
cerebrospinal ﬂuid, joint, bone or synovial ﬂuid), or from
samples obtained from deep body site aspirates, or from intra-
operative specimens. In cases where it was unclear whether
infections were invasive (e.g., intra-abdominal or soft-tissue
cultures), they were deemed to represent invasive disease only
after a review of all available laboratory information, the
specimen type, the physician’s specialty, and comments on
request forms, e.g., whether information was provided that a
sample was from a patient with STSS, NF or puerperal sepsis.
Clinical information was requested retrospectively for all
475 patients with invasive S. pyogenes infections, and complete
data were available for 165 of these patients. The dataset
included information concerning the gender and age of the
patient and diagnoses, including certain speciﬁed diagnoses
(STSS, septicaemia, NF, pneumonia, cellulitis and puerperal
sepsis). Information concerning the clinical course included
the following parameters ⁄ information: presence of shock,
adult respiratory distress syndrome, presence of artiﬁcial
ventilation, renal failure, soft-tissue necrosis, disseminated
intravascular coagulation, increased liver enzymes and exan-
thema. Therapeutic measures were classiﬁed into surgical
interventions (debridement, fasciotomy, abdominal surgery,
gynaecological surgery) and further medical treatment, which
included detailed data regarding antibiotic therapy and the
use of non-steroidal anti-inﬂammatory drugs. Possible risk-
factors analysed included the presence of any immunosup-
pression, concomitant surgery, pregnancy, intravenous drug
abuse, diabetes mellitus, infection of the respiratory tract,
chronic vascular disease, hypertension and varicella infection.
Data concerning diagnoses and risk-factors could be categor-
ised under multiple clinical syndromes according to O’Brien
et al. [8]. In brief, STSS was conﬁrmed by reviewing the charts
and assessing whether the published case deﬁnition was met
[7], or by noting that a diagnosis of STSS had been made by the
treating physician. Cases were categorised as NF if this
diagnosis was documented in the chart, or if necrosis of tissue
was noted on a pathological or surgical report. Skin and soft-
tissue infections included cellulitis, infected ulcers, erysipelas,
wound infections, lymphangitis, lymphadenitis and phlebitis.
Nosocomial infection was presumed if the culture was taken
>3 days after admission.
Microbiological investigations
In total, 464 isolates were available for emm typing and
characterisation of pathogenicity factors (isolates from 11 of
the 475 patients were no longer viable). Isolates were identiﬁed
by haemolysis on sheep blood agar, Lanceﬁeld grouping using
a commercially available agglutination technique (Slidex,
Streptokit; bioMe´rieux, Marcy-L’Etoile, France), and the pyr-
rolidonyl–arylamidase test. The presence of emm genes was
determined by PCR using ‘all M primers’ as described
previously [9]. PCR products were puriﬁed and sequenced
on an automated ABI 390 DNA sequencer (Applied Biosys-
tems, Weiterstadt, Germany). S. pyogenes CS101 (emm49) was
used as a reference strain. The nucleotide sequence encoding
the N-terminal hyper-variable portion of the M protein was
compared to sequences deposited at the CDC (http://
www.cdc.gov/ncidod/biotech/strep/strepblast.htm). When
a high degree of identity (95% identity with the 5¢-terminal
portion of a known sequence) was observed, the nucleotide
sequence was given the corresponding type designation. The
presence of the speA, speC, speF (employed as a control) or ssa
genes was determined by PCR using individual primer pairs
as described previously [10].
Statistical analysis
The annual number of cases was summarised in terms of
minimum, maximum and mean values, with corresponding
standard deviation. The age distribution in the full sample, as
well as in the subgroups of surviving and deceased patients,
was condensed by mean and median values with correspond-
ing measures of variation (standard deviation, inter-quartile
range). Categorial variables were given as absolute and
corresponding relative frequencies. Multiple logistic regres-
sion analysis was used to determine the effects of the binary
variables of age, STSS, NF, meningitis, shock, renal failure,
disseminated intravascular coagulation, adult respiratory dis-
tress syndrome, acidosis and infections by emm1, emm3 or
emm28 on fatal outcome. A dichotomised version was used in
the analysis to allow easier interpretation of the variable age
(group 1, £30 years; group 2, >30 years). As there was a
comparatively large number of independent factors, initial
bivariate logistic regression analyses were conducted in order
to select relevant risk-factors (risk-factors with p £0.2) for the
ﬁnal multiple logistic regression model. As higher age, STSS
and infections by emm type 1 strains have been described
previously as risk-factors for fatal outcome [1,3,4,11–13], these
parameters were used in the multiple logistic regression
model, independent of their p value in bivariate analyses. In
analysing the ﬁnal multiple logistic regression model, the
forward selection procedure was used to select statistically
signiﬁcant risk-factors, with p values, ORs and corresponding
95% CIs being calculated for these factors only; p £0.05 was
interpreted as being statistically signiﬁcant. All statistical
analyses were conducted using the SAS statistical analysis
software package v.9.1 (SAS Inc., Cary, NC, USA).
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RESULTS
In total, 475 cases of invasive GAS disease were
identiﬁed between 1 July 1996 and 31 December
2002. The 475 invasive isolates were obtained
from blood (n = 251), skin lesions (n = 96), lung
(biopsies, autopsy material) (n = 17), pleural ﬂuid
(n = 8), synovial ﬂuid (n = 7), cerebrospinal ﬂuid
(n = 10), peritoneal ﬂuid (n = 7) and other spec-
imens (n = 79). The number of reported cases for
each year were: 1996 (part), 16; 1997, 42; 1998, 97;
1999, 66; 2000, 95; 2001, 79; and 2002, 80.
After wider acceptance of the services of the
NRCS in 1998, the mean annual number of
reported cases during 1998–2002 was 83.4 (min-
imum 66; maximum 97; SD 12.8). The estimated
annual incidence of invasive GAS disease for
1997–2002 was 0.1 cases ⁄ 100 000 individuals,
based on population data for 2003 (82.4 million
inhabitants) (http://www.destatis.de). The num-
ber of reported cases did not vary signiﬁcantly
from year to year during this period. Complete
clinical data were available for 165 of the 475
cases; clinical records were available in 1996 for
only six patients, and for 13.3–20.6% of the cases
in other years.
In total, 45 different emm types were identiﬁed
among the 464 emm-typed isolates (Table 1). The
speA, speC and ssa genes, which have been found
to be associated with prophage elements, were
present at variable frequencies in different emm
types, with the highest rates of speA and speC
being found in emm1 (speA, 93.6%) and emm4
(speC, 94.7%), respectively (Table 1). The propor-
tion of disease caused by each emm type varied
over the course of time and by surveillance area.
Disease caused by emm types 1 and 12 was
detected in every year of this study, with peaks
in 1998 and 2002, while emm28 was isolated most
frequently in 2000 and 2001, with November
being the peak month. During 1998 and 1999,
invasive infections caused by emm3 were most
prevalent (data not shown).
Differences in the seasonal occurrence of inva-
sive S. pyogenes disease were observed. A peak of
disease was observed during winter (January–
March), and a low point during the months of
summer and the early months of winter (July–
December). Geographical differences in the
distribution of invasive S. pyogenes infections
were also noted. Since a tight surveillance system
with high compliance in reporting was not estab-
lished at the time of collecting these isolates, these
differences were related, at least in part, to
different rates of submission of isolates from the
states within the Federal Republic of Germany.
The incidence of infection was slightly higher
among females (50.9% of all cases), but the male
case fatality rate (CFR) (48.1%) was far higher
than that of females (34.5%).
Age distribution in relation to the CFR is
shown in Table 2. The CFR increased with
higher age. While patients aged <30 years had
comparatively low CFRs (11.1–20.8%), the CFR
for patients aged >30 years clearly increased,
with a peak at 65.2% in patients aged 60–69
years. Compared with the mean age of
38.6 years (SD 23.4 years), patients who died
(mean 47.2 years; SD 20.9 years) were older than
patients who survived (mean 32.7 years;
Table 1. Distribution of emm types and superanti-
gen ⁄ toxin genes among 464 Streptococcus pyogenes isolates
from invasive disease in Germany, 1996–2002
emm
type
No. of
isolates % speA % speC % ssa %
1 173 37.3 162 93.6 19 11 2 1.2
3 38 8.2 35 92.1 1 2.6 25 65.8
4 19 4.1 2 10.5 18 94.7 14 73.7
6 13 2.8 11 84.6 7 53.8 1 7.7
11 14 3 3 21.4 8 57.1 0 0
12 27 5.8 1 3.7 12 44.4 1 3.7
28 42 9.1 3 7.1 31 73.8 2 4.8
75 13 2.8 0 0 4 30.8 0 0
77 22 4.7 1 4.5 14 63.6 0 0
89 16 3.4 0 0 4 25 0 0
Othersa 87 18.8 15 17.2 34 39.1 7 8
Overall 464 100 233 50.2 152 32.8 52 11.2
aThe category ‘others’ includes the following emm types (number of isolates in
parentheses): types 2 (8), 5 (3), 8 (1), 9 (1), 18 (5), 22 (3), 25 (1), 29 (2), 43 (1), 44 ⁄ 61 (3),
49 (5), 50 (2), 53 (1), 59 (1), 63 (3), 65 ⁄ 69 (1), 66 (1), 68 (1), 74 (2), 76 (1), 78 (4), 81 (1),
82 (2), 83 (6), 85 (4), 90 (2), 94 (4), 95 (3), 102.1 (1), 104 (1), 116 (1), 118 (9), 122 (1), 123
(1), st2917 (1).
Table 2. Age distributiona and case fatality rate (CFR) for
165 cases of invasive Streptococcus pyogenes disease in
Germany
Age group
(years) No. of cases % CFR (%)
0–5 24 14.5 20.8
6–9 7 4.2 14.3
10–19 9 5.5 11.1
20–29 16 9.7 18.8
30–39 31 18.8 45.2
40–49 19 11.5 57.9
50–59 19 11.5 42.1
60–69 23 14 65.2
‡70 17 10.3 52.9
Total 165 100 40.6
aMean age (standard deviation): all patients, 38.6 (23.4) years; surviving patients,
32.7 (24) years; deceased patients, 47.2 (20.9) years. Median age (inter-quartile
range): all patients, 38 (36) years; surviving patients, 31 (44) years; deceased
patients, 46 (27) years.
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SD 24 years). The proportions of patients with
invasive S. pyogenes disease and various under-
lying diseases or risk-factors are shown in
Table 3. All seven cases of varicella infection
occurred in patients aged <10 years.
An association was assumed between emm type
and clinical syndromes. In a univariate analysis,
40 emm1 strains were associated with STSS
(76 reported cases) and seven with pneumonia
(14 reported cases); nine emm3 strains were
associated with STSS, and six of nine reported
pregnancy-related infections were associated with
emm1 strains. However, these associations were
not statistically signiﬁcant.
There was a CFR of 53.8% among the 80
patients who did not undergo surgical interven-
tions, compared with 28.2% in patients following
surgical interventions (n = 85). However, these
two groups were not stratiﬁed with respect to
patient age, indications for surgery, clinical status
when intervention was initiated, etc. The surgical
interventions comprised 29 debridements, 18
fasciotomies, seven abdominal procedures and
ﬁve gynaecological procedures. The overall CFR
for invasive GAS disease was 40.6%, but CFRs
varied substantially according to clinical syn-
drome (Table 4).
Results of the multiple logistic regression anal-
ysis are presented in Table 5. Shock (included in
step 1; p 0.0004; OR 5.96, 95% CI 2.22–15.99), age
>30 years (included in step 2; p 0.0003, OR 7.42,
95% CI 2.51–21.94) and adult respiratory distress
syndrome (included in step 3; p 0.0303, OR 2.86,
95% CI 1.11–7.39) showed a statistically signiﬁ-
cant impact on fatal outcome; no statistically
signiﬁcant effect of the remaining factors could be
shown (p >0.05).
Table 3. Underlying diseases ⁄ risk-factors and case fatality
rates (CFRs) for 165 cases of invasive Streptococcus pyogenes
disease in Germany
Underlying disease ⁄ risk-factors No. of cases % CFR (%)
Skin lesion 50 30.3 34
Infected lesion 9 5.5 66.7
Usage of NSAID 22 13.3 40.9
Immunosuppression 11 6.7 36.4
Surgery 10 6.1 60
Delivery 9 5.5 33.3
Intravenous drug abuse 7 4.2 42.9
Exposure to infected individualsa 4 2.4 25
Diabetes mellitus 14 8.5 42.9
Hypertension 9 5.5 33.3
Varicella infection 7 4.2 14.3
Totalb 152 100 40.6
NSAID, non-steroidal anti-inﬂammatory drug.
aThree individuals (two were aged 0–5 years and one was aged 32 years) with
S. pyogenes-associated diseases and one individual (0–5 years) with varicella.
bThe number of patients with underlying diseases ⁄ risk-factors does not add up to
165, as not every patient included in the study had an underlying disease or risk-
factor.
Table 4. Case fatality rates (CFRs) for 165 cases of invasive
Streptococcus pyogenes disease in Germany, grouped
according to clinical diagnosis
Diagnosis No. of casesa % CFR (%)
STSS 76 46.1 57.9
Sepsis 77 46.7 39
NF 55 33.3 40b
Pneumonia 14 8.5 35.7
Cellulitis 11 6.7 36.4
Puerperal sepsis 6 3.6 16.7
NF, necrotising fasciitis; STSS, streptococcal toxic shock syndrome.
aThe total number of cases does not add up to 165 (100%), as certain patients had a
combination of diagnoses. Corresponding percentages are given with respect to all
165 cases.
bThe CFR for patients with NF was 33.3% in patients without STSS and 48% in
patients with STSS.
Table 5. Factors associated with
fatal outcome in 165 cases of inva-
sive Streptococcus pyogenes infections
in Germany, 1996–2002
Factors contributing
to fatal outcome
p value
(bivariate
logistic
regression)
Results of the
forward
selection
procedure
p value
(multiple
logistic
regression)
Odds
ratio
95%
LCL
95%
UCL
Age (‡30 years) <0.0001 Entered (step 2) 0.0003 7.421 2.510 21.943
Syndrome
Meningitis 1.0000 – – – – –
STSS <0.0001 Not entered – – – –
NF 1.0000 – – – – –
Clinical course
Shock <0.0001 Entered (step 1) 0.0004 5.961 2.222 15.992
ARDS or
ventilation
<0.0001 Entered (step 3) 0.0303 2.858 1.105 7.390
Renal failure 0.0023 Not entered – – – –
DIC 0.0395 Not entered – – – –
MOF <0.0001 Not entered – – – –
Acidosis 0.0080 Not entered – – – –
Emm type
emm1 0.2375 Not entered – – – –
emm3 0.2558 – – – – –
emm28 1.0000 – – – – –
ARDS, acute respiratory distress syndrome; DIC, disseminated intravascular coagulation; LCL, lower conﬁdence
limit; MOF, multi-organ failure; NF, necrotising fasciitis; UCL, upper conﬁdence limit; STSS, streptococcal toxic
shock syndrome.
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Eleven (6.7%) of the 165 cases were categorised
as nosocomial infections. All patients had under-
gone surgery within the 3-day period before
infection was diagnosed. These surgical interven-
tions included elective hysterectomy, struma
surgery, reconstruction of an inguinal hernia,
appendicectomy, orthopaedic surgery, liposuc-
tion, intestinal surgery and surgery following an
accident. Six of these 11 patients died. Strains of
emm type 1 were isolated from swabs and blood
cultures of four patients, and emm types 6 and 28
were isolated from two patients each.
Of the nine cases that were related to preg-
nancy, six (66.7%) were categorised as nosoco-
mial infections. Of these cases, ﬁve experienced a
natural delivery and four underwent a Caesarean
section. Each case had individual risk-factors, e.g.,
birth-related risk-factors (such as breech position
or placental insufﬁciency), or exposure to indi-
viduals with an S. pyogenes infection or who were
suffering from recurrent pharyngitis. As men-
tioned above, emm1 was by far the most prevalent
emm type (six of nine infections) among the cases
of puerperal sepsis.
DISCUSSION
The present investigation is the ﬁrst comprehen-
sive epidemiological study of invasive S. pyogenes
infections in Germany. Enhanced surveillance of
invasive S. pyogenes infections was implemented
in Germany following the cluster of cases of NF
detected in south-west England (Gloucestershire)
during the 1990s [14]. Between 1996 and 2002, 475
cases of invasive GAS disease were reported
to the German NRCS. In 1998–2002, the mean
annual number of reported cases was 81.6,
with an estimated annual incidence of 0.1 cases ⁄
100 000 individuals. Results from predominantly
northern European countries have consistently
shown higher rates of invasive S. pyogenes infec-
tions [3], with incidence rates of >1 ⁄ 100 000 indi-
viduals in the UK [3], Sweden [15] and The
Netherlands [4]. In contrast, the Czech Republic
[16] and Italy [17] have reported lower incidences
of 0.06–0.4 ⁄ 100 000 individuals, which are in
the same range as that found in the present
investigation.
These large variations in incidence among
different countries may arise, at least in part,
from differences in surveillance systems, blood
culture sampling rates, and the identiﬁcation of
individual cases, as recently shown for invasive
pneumococcal disease in Germany [18,19]. Since
invasive S. pyogenes disease is not a notiﬁable
disease in Germany (only reports of outbreaks are
mandatory), the laboratory-based surveillance
system used for the present study was entirely
voluntary at the time of the study. In contrast to
other European countries, Germany has no net-
work of ofﬁcial public health laboratories (most
microbiological laboratories are privately owned),
which may also explain the apparent low
incidence. Seasonal variation followed patterns
observed elsewhere [3,4], with peaks in winter
and early spring.
In the present study, emm1 was the most
prevalent emm type among S. pyogenes isolates
causing invasive disease, as has been observed
previously in the USA [8] and some European
countries [1,3,4,11,12]. All isolates were tested for
the presence of virulence factor genes, including
those coding for superantigens. The speA and speC
genes were highly associated with particular emm
types, and the highest frequency of speA (93.6%)
was found in emm1 isolates. Schmitz et al. [20]
reported that all but one of 239 emm1 and emm3
isolates carried a speA allele and lacked a speC
gene, suggesting that the presence of speA affects
the acquisition of a speC gene [20]. In addition,
Vlaminckx et al. [4] speculated that the presence
of speA in combination with smeZ in emm1 strains
might contribute to intrinsic virulence, which is
supported by the high CFR seen among infections
caused by emm1 isolates in the present study.
Older age (>30 years) was a predictor of mor-
tality in the present study, as was also found in
population-based studies performed in the USA
[8] and Canada [13]. However, in contrast to these
previous studies, the presence of STSS, meningitis,
pneumonia and infection with emm1 or emm3
strains were not predictors of fatal outcome in a
multiple logistic regression analysis.
It is of note that the CFR reported in the present
study is one of the highest reported to date. In a
study from the USA, the overall CFR for invasive
GAS disease was 12.5%, but the highest CFR was
observed among patients with STSS (44.5%) [8].
Explanations for these marked variations may lie
in differences in study populations and in the
threshold of disease severity that prompts sterile-
site culturing and the referral of isolates to a
reference laboratory, which may, in turn, result in
a bias towards the most severe cases and a
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consequently higher CFR. This may not be a
major factor for patients with meningitis [19], but,
for the reasons mentioned above, the spectrum of
clinical disease from which S. pyogenes blood
isolates are derived probably varies in different
regions, thereby possibly inﬂuencing the emm
type distribution.
Current strategies for preventing morbidity and
mortality resulting from invasive S. pyogenes
infection are limited. Some cases may be pre-
vented through the increased use of varicella
vaccine in children, which forms part of a gener-
alised vaccination programme introduced in
Germany during 2005. Chemoprophylaxis of
selected contacts of patients with invasive infec-
tion, additional infection control procedures, and
prompt investigation of outbreaks in hospitals and
nursing homes are all measures that may help to
reduce the high burden of S. pyogenes disease [8].
Moreover, several promising candidate vaccines
are currently in clinical development [21,22]. The
present study documents the high burden of
disease caused by invasive S. pyogenes infections
in Germany, and underscores the need for an
active population-based surveillance programme.
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